Boston scientific agent™ drug-coated balloon demonstrates superiority to uncoated balloon angioplasty in the agent ide trial

Data from first coronary dcb study in u.s. meet 12-month primary endpoint, demonstrate low adverse event rates with agent dcb marlborough, mass. and san francisco , oct. 25, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced positive 12-month results from the pivotal agent ide clinical trial of the agent™ drug-coated balloon (dcb).1 primary endpoint findings from this first clinical trial in the u.s. to evaluate the safety and effectiveness of using a dcb to treat coronary in-stent restenosis (isr) were presented in a late-breaking clinical trial session at transcatheter cardiovascular therapeutics (tct), the annual scientific symposium of the cardiovascular research foundation.
BSX Ratings Summary
BSX Quant Ranking